Theramex Deal History & Licensing Activity
Theramex is a mid-size pharma headquartered in UK. Over the past three years, Theramex has been involved in 2 licensing and acquisition transactions, with a primary focus on Small Molecules (2 deals). The company currently has 2 active clinical trials, primarily in Women's Health.
Deals (12mo)
1
Active Trials
2
Top Modality
Small Molecules
Focus Area
Women's Health
Theramex Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Theramex in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Linzagolix (YSELTY) | Kissei Pharmaceutical | Small Molecules | Approved | license | Apr 2026 |
Theramex Pipeline Focus
Therapeutic areas and modalities where Theramex is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Theramex Strategic Signals
Key indicators of Theramex's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Theramex Clinical Pipeline
Theramex has 2 active clinical trials across 1 development phase.
2
Phase 4
See How Your Asset Matches Theramex's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Women's Health assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Theramex Licensing & Deal Activity
Theramex is a mid-size pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Theramex ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Theramex include Women's Health (3 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, Theramex has shown particular interest in small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Theramex and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Theramex's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.